A-002

DRUG2 trials

Sponsors

Anthera Pharmaceuticals

Conditions

Coronary Artery DiseaseCoronary Artery Disease (CAD)

Phase 2

PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery Disease

CompletedNCT00455546

Anthera PharmaceuticalsCoronary Artery Disease (CAD)

Start: 2007-04-30End: 2007-09-30Updated: 2010-02-02

PLASMA 2 Trial: Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease

CompletedNCT00525954

Anthera PharmaceuticalsCoronary Artery Disease

Start: 2007-09-30End: 2007-12-31Target: 120Updated: 2008-01-07

Related Papers

Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease.

2010-11-1639 citations

Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial.

2009-02-0184 citations